Therapeutic potential of COX-2 inhibitors in arthritis

Bibliography

• MCNEIL JM: Americans with disabilities: 1991–1992. Current population reports. Washington (DC): US Bureau of the Census. (1993).
   Google Scholar
• YELIN E, CALLAHAN LF: The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Group. Arthritis Rheum. (1995) 38:1351–1362.
   PubMed Web of Science ®Google Scholar
• RODNAN GP, BENEDEK TG: The early history of antirheumatic drugs. Arthritis Rheum. (1970) 13:145.
   PubMed Web of Science ®Google Scholar
• MACLAGAN TJL: Lancet (1876) 342 In: Nonsteroidal Anti-inflammatory Drugs, Mechanisms and Clinical Use. Lewis AJ and Furst DE (Eds.) Marcel Dekker, Inc. New York/Basel.
   Google Scholar
• LIM R, GUZMAN R, RODGER DW et al.: Site of action on narcotic and non-narcotic analgesics determined by blocking bradykinin-evoked visceral pain. Arch. Int. Pharnacodyn. Ther. (1964) 152:25.
   PubMedGoogle Scholar
• KANTOR TB. Concepts in pain control. Semi]. Arthritis Rheum. (1989) 18\(Suppl. 2)94–99.
   Google Scholar
• ABRAMSON SB, WEISSMANN G: The mechanisms of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. (1989) 32:1–9.
   PubMed Web of Science ®Google Scholar
• •Review of NSAID mechanisms of action. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol.) (1971) 231:232-235. Landmark advance.
   Google Scholar
• MORITA I, SCHINDLER M, REGIER MK et al.: Different intracellular locations for prostaglandin endoperoxide H synthase-1 and 2. J. Bia. Chem. (1995) 270:10902–10908.
   PubMed Web of Science ®Google Scholar
• KRAEMER SA, MEADE SA, DEWITT DL: Prostaglandin endoperoxide synthetase gene structure: Identification of the transcriptional start site and 5'-flanking regulatory sequences. Arch. Biochem. Biophys. (1992) 293:391-400. CROFFORD LJ, WILDER R:, RISTIMAKI AP et al.: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-lbeta, phorbol ester, and corticosteroids. j Clin. Invest. (1994) 93:1095–1101.
   Google Scholar
• SMITH WL, DEWITT DL: Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. (1995) 15:179–194.
   PubMed Web of Science ®Google Scholar
• CROFFORD COX-1 and COX-2 tissue expression: implications and predictions. j Rheumatol. (1997) 2 arthritis 4:15–19.
   Google Scholar
• •Succinct review of COX-1 gi COX-2 regulation and expression.
   Google Scholar
• SEIERT K, ZHANG Y, LEAHY K et al.: Pharmacological and biochemical demonstration of the role of cycloxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA (1994) 91:12013–12017.
   PubMed Web of Science ®Google Scholar
• KOZAK KR, ROWLINSON SW, MARNETT LJ: Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyseryl prostaglandins by cyclooxygnease-2. Biol. Chem. (2000) 275:33744–33749.
   Web of Science ®Google Scholar
• ANDERSON GD, HAUSER SD, BREMER ME et all: Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and IL-6 in rat adjuvant arthritis. j Clin. Invest. (1996) 97:2672–2679.
   PubMed Web of Science ®Google Scholar
• SANO H, HLA T, MAIER JAM et al.: In vivo cyclooxygenase expression in synovial tissue of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant streptococal cell wall arthritis. j Clin. Invest. (1992) 89:97–108.
   PubMed Web of Science ®Google Scholar
• MEADE EA, SMITH WL, DEWITT DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other nonsteroidal anti-inflammatory drugs. _J. Biol. Chem. (1993) 268:1095–1101.
   PubMedGoogle Scholar
• PATRIGANI P, PANARA MR, SCIULLI MG etal.: Biochemical and pharmacolgical characterisation of the cyclooxygenase activity of human blood prostagandin endoperoxide synthases. I Pharm. Esp. Therap. (1994) 271:1705–1712.
   Google Scholar
• LUONG C, MILLER A, BARNETT J et al.: The structure of human cyclooxygenase-2: conservation and flexibility of the NSAID binding site. Nat. Struct. Biol. (1996) 3:927–933.
   PubMedGoogle Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644–648.
   PubMed Web of Science ®Google Scholar
• ••Mechanism of COX-2 selectivity.
   Google Scholar
• MARNETT LJ, ROWLINSON SW, GOODWIN DE et al.: Arachidonic acid oxygenation by COX-1 and COX-2 - mechanism s of catalysis and inhibition. Biol. Chem. (1999) 274:22903–22906.
   Web of Science ®Google Scholar
• VANE JR, WARNER TD: Nomenclature for COX-2 inhibitors. Lancet (2000) 356:1373–1374.
   PubMed Web of Science ®Google Scholar
• MOBIC PRODUCT INFORMATION, Boehringer Ingelheim.
   Google Scholar
• NOBLES, BALFOUR JA: Meloxicam. Drugs (1996) 51:424–432.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, McMAHOL AT: Do cyclooxygenase-2 inhibitors provide benefits similar tothose of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. (2000) 132:134–143.
   Web of Science ®Google Scholar
• TURCK D, ROTH W, BUSCH U: A review of the clinical phamacokinetics of meloxicam. Br j RheumatoL (1996) 35\(Suppl. 1):56–60.
   Google Scholar
• FURST DE: Meloxicam: selective COX-2 inhibition in clinical practice. &min. Arthritis. Rheum. (1997) 26:21–27.
   PubMed Web of Science ®Google Scholar
• •Summarises clinical experience with meloxicam.
   Google Scholar
• CELEBREX PRODUCT INFORMATION, G.D. Searle and Co., December (1999).
   Google Scholar
• MASFERRER JL, ZWEIFEL BS, MANNING PT et al.: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non ulcerogenic. Proc. Natl. Acad. Sri. USA (1994) 91:3228–3232.
   PubMed Web of Science ®Google Scholar
• CLEMETT D, GOA KL: Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis, and acute pain. Drugs (2000) 59:957–980.
   Google Scholar
• •Summarises pharmacoltinetics and clinical experience with celecoxib.
   Google Scholar
• VIOXX PRODUCT INFORMATION, Merck and Co., September (1999).
   Google Scholar
• EHRICH EW, DALLOB A, DELEPELIERE et al.: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in dental pain model. Clin. Pharm. Ther (1999) 65:336–348.
   PubMed Web of Science ®Google Scholar
• SCOTT LJ, LAMB HM: Rofecoxib. Drugs (1999) 58:499–505.
   PubMed Web of Science ®Google Scholar
• •Summarises pharmacoltinetics and clinical experience with rofecoxib.
   Google Scholar
• RIENDEAU D, PERCIVAL MD, BRIDEAU C et al.: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cycloowygenase-2. I PharmacoL Esp. Ther. (2001) 296:558–566.
   PubMed Web of Science ®Google Scholar
• TALLEY JJ, BROWN DL, CARTER JS et al.: 4- [5-methyl-3-phenylisoxazol-4-yll - benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. _J. Med. Clin (2000) 43:775–777.
   PubMed Web of Science ®Google Scholar
• LUND B, DISTEL M, BLUHMKI E: A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scam/. Rheumatol. (1998) 27:32–37.
   PubMed Web of Science ®Google Scholar
• YOCUM D, FLEISCHMANN R, DALGIN P etal.: Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. Arch. Intern. Med. 2000; 160: 2947–2954.
   Google Scholar
• DEQUEKER J, HAWKEY C, KAHAN A eta].: Improvement in gastrointestinal tolerability of the selective cyclooxygnease (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. j Rheumatol. (1998) 37:937–945.
   Google Scholar
• HAWKEY C, KAHAN A, STEINBRUCK K eta].: Gastrointestinal tolerability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients. The meloxicam large scale international study safety assessment (MELISSA). Br I RheumatoL (1998) 37:946–951
   Google Scholar
• •Together with SELECT trial demonstrated comparable efficacy with improved safety.
   Google Scholar
• HOSIE J, DISTEL MR, BLUHMKI E: Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study. Clin. Drug. Invest. (1997) 13:175–184.
   Web of Science ®Google Scholar
• GOEI THS, LUND B, DISTEL MR, BLUHMKI E: A double-blind, randomized trial to compare meloxicam 15 mg with dicofenac 100 mg in the treatment of osteoarthritis of the knee. Ostoearthritis Cartilage (1997) 5:283–288.
   PubMed Web of Science ®Google Scholar
• PROUSE PJ, BEVIS PJ, BLUHMKI E, DISTEL M: Evaluation of the safety, tolerability, and efficacy of meloxicam inpatients with osteoarthritis. Gum. Ther. (1996) 18:429–439.
   PubMed Web of Science ®Google Scholar
• SIMON LS, LANZA FL, LIPSKY PE etal.: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum (1998) 41:1591–1602.
   Google Scholar
• •Initial report of benefit with celecoxib.
   Google Scholar
• BENSEN WG, FIECHTNER JJ, MCMILLEN JI et al.: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo OM. Proc. (1999) 74:1095–105.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GW, ETTLINGER RE, RUDERMAN EM etal.: Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized controlled trial. Clin. Rheumatol. (2000) 6:65–74.
   Google Scholar
• HUBBARD RC, GEIS GS, WOODS EM et au.: Efficacy and celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip [abstract] . Arthritis Rheum. (1999) 42(Suppl.):144.
   Google Scholar
• EHRICH EW, SCHNITZER TJ, HARRISM et au.: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. j Rheumatol (1999) 26:2438–2447.
   Google Scholar
• DAY R, MORRISON B, LUZA etal.: Arandomized trial of the efficacy and tolerability of the COX- inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Arch. Intern. Med. (2000) 160:1781–1787.
   Google Scholar
• CANNON GW, CALDWELL JR, HOLT P et al: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum. (2000) 43:978–987.
   PubMed Web of Science ®Google Scholar
• •Largest trial with rofecoxib in osteoarthritis.
   Google Scholar
• GEBA GP, WEAVER LA, SCHNITZER TJ et al.: A comparison of rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis. Arthritis Rheum. (2000) 43(Suppl.):S384.
   Google Scholar
• •Head-to-head comparison of celecoxib and rofecoxib showing comparable efficacy and safety.
   Google Scholar
• LEMMEL EM, BOLTEN W, BURGOS-VARGAS R et al.: Efficacy and safety of meloxicam inpatients with rheumatoid arthritis. j Rheumatol (1997) 24:282–290.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, DISTEL M, BLUHMKIE: A double-blind, three-week study to compare the efficacy and safetyof meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br Rheumatol. (1996) 935 (Suppl. 1):17–21.
   Google Scholar
• WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et al: A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol (1996) 35 (Suppl. 1):22–28.
   Google Scholar
• HUSKISSON EC, GHOZLAN R, KURTHEN et al.: A long-term study to evaluate the safety and efficacy of meloxicam therapy inpatients with rheumatoid arthritis. Br j Rheumatol. (1996) 35\(Suppl. 1):29–34.
   Google Scholar
• FURST DE, HALL DB, ROSZKO PJ: Efficacy and safety of meloxicam in the treatment of rheumatoid arthritis: results of a Phase III double-blind, placebo controlled trial. Arthritis Rheum. (2000) 43(Suppl.):5225.
   Google Scholar
• EMERY E ZEIDLER H, KVIEN TK et al: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (1999) 354:2106–2111.
   PubMed Web of Science ®Google Scholar
• SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 282:1921–1928.
   PubMed Web of Science ®Google Scholar
• SCHNITZER TJ, TRUITT K, FLISCHMANN R et al: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clio. Ther. (1999) 21:1688–1702.
   PubMed Web of Science ®Google Scholar
• BOMBARDIER C, LAINE L, REICIN et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng. J. Med. (2000) 343:1520–1528.
   PubMed Web of Science ®Google Scholar
• •Report of the VIGOR trial.
   Google Scholar
• DOUGADOS M, BEHIER JM, JOLCHINE et al.: Efficacy of celecoxib, a cyclooxygenase inhibitor, in the treatment of ankylosing spondylitis. Arthritis Rheum. (2001) 44:180–185.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology (1999) 38:235–244.
   PubMed Web of Science ®Google Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib s. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA (2000) 284:1247–1255.
   Google Scholar
• •Report of the CLASS trial.
   Google Scholar
• WHELTON A, FORT JG, PUMA JA et al: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. (2001) 8:85–95.
   PubMedGoogle Scholar
• TINDALL EA: Celecoxib does not affect index joint x-rays in osteoarthritis patients with long-term exposure. Arthritis Rheum. (2000) 43(Suppi.):5224.
   Google Scholar
• MASTBERGEN SC, LAFEBER FPJG, BIJLSMA WJ etal.: Inflammation induced cartilage damage is COX-2 mediated and can be prevented by celecoxib. Arthritis Rheum. (2000) 43(Suppl.):5349.
   Google Scholar